Total (TOT:NYS) and Vertex Pharmaceuticals (VRTX:NAS) Upgraded

Stockcalc – Free Trial

Have a free look inside the StockCalc website at www.stockcalc.com



I have used the analysis tools on the website stockcalc.com to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com/toppicks.aspx.

Upgraded Stocks on NYSE, NASDAQ, AMEX, TSE, and TSX

Today we are looking at companies whose share price has been upgraded by at least one analyst in the last few days.

Why Do Companies Get Upgraded?

Companies can get upgraded for a number of reasons, but primarily due to improved future earnings potential due to new contracts, new products, cost savings or restructuring.

In the list below you can see the number of analysts we have in the StockCalc database along with the number of buy-hold-sell on the company.

Today’s Data on NYSE, NASDAQ, AMEX, TSE, and TSX

Below we have today’s data for companies listed on all of the New York Stock Exchange, NASDAQ Stock Exchange, American Stock Exchange, Toronto Stock Exchange, and TSX Venture Exchange.

New York Stock Exchange
Symbol Name Buy Out Perform Hold Under Perform Sell No Opinion Mean Rating Prev Mean Rating Mean Label
TOT Total SA 3 1 3 0 0 0 4.0000 3.8333 Outperform
BCS Barclays PLC 3 1 0 0 0 0 4.7500 4.5000 Buy
NOK Nokia Oyj 3 1 3 0 0 0 4.0000 3.8571 Outperform
EFX Equifax Inc 9 2 2 0 0 0 4.5385 4.5000 Buy
TRU TransUnion 2 0 0 1 0 0 4.0000 3.5000 Outperform
ECA Encana Corp 13 5 1 1 0 0 4.5000 4.4737 Outperform
NVR NVR Inc 0 0 2 0 0 0 3.0000 2.5000 Hold
FDS FactSet Research Systems Inc 0 0 5 0 2 0 2.4286 2.3333 Underperform
PHM PulteGroup Inc 3 1 2 0 0 0 4.1667 4.0000 Outperform
ARGO Argo Group International Holdings Ltd 1 0 0 0 0 0 5.0000 1.0000 Buy
CLS Celestica Inc 3 0 8 0 0 0 3.5455 3.4000 Outperform
Toronto Stock Exchange
Symbol Name Buy Out Perform Hold Under Perform Sell No Opinion Mean Rating Prev Mean Rating Mean Label
ECA Encana Corp 13 5 1 1 0 0 4.5000 4.4737 Outperform
CLS Celestica Inc 3 0 8 0 0 0 3.5455 3.4000 Outperform
HRX Heroux-Devtek Inc 1 2 4 0 0 0 3.5714 3.3333 Outperform
YGR Yangarra Resources Ltd 6 5 1 0 0 0 4.4167 4.3636 Outperform
BOS Airboss of America Corp 0 2 3 0 0 0 3.4000 3.2000 Hold
ONC Oncolytics Biotech Inc 2 2 1 0 0 0 4.2000 4.0000 Outperform
NASDAQ
Symbol Name Buy Out Perform Hold Under Perform Sell No Opinion Mean Rating Prev Mean Rating Mean Label
GILD Gilead Sciences Inc 4 0 4 0 0 0 4.0000 3.8571 Outperform
VRTX Vertex Pharmaceuticals Inc 5 0 3 0 0 0 4.2500 4.1429 Outperform
INFO IHS Markit Ltd 1 0 4 0 0 0 3.4000 3.0000 Hold
SRPT Sarepta Therapeutics Inc 4 0 1 0 0 0 4.6000 4.5000 Buy
TSRO Tesaro Inc 3 0 2 0 0 0 4.2000 4.0000 Outperform
PBYI Puma Biotechnology Inc 1 0 1 0 0 0 4.0000 3.0000 Outperform
AKRX Akorn Inc 1 1 2 0 0 0 3.7500 3.6667 Outperform
ONCY Oncolytics Biotech Inc 2 2 1 0 0 0 4.2000 4.0000 Outperform
ADIL Adial Pharmaceuticals Inc 1 0 0 0 0 0 5.0000 0.0000 Buy

Let’s look at a few companies…

Lets look at a couple of the companies on this list to get a better understanding of them.

TOT:NYS Total

http://www.total.com
Total has 98277 employees and is headquartered in France.
Total SA is an integrated oil and gas company. It is engaged in exploring, producing, refining oil and gas and related products.

VRTX:NAS Vertex Pharmaceuticals

http://www.vrtx.com
Vertex Pharmaceuticals has 2300 employees and is headquartered in United States.
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.

Free Valuation

Run a valuation on any of the companies listed above at www.stockcalc.com/valureport.aspx or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports.

The content presented here is in part from the website stockcalc.com and is provided on an as is or as available basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.